Cingulate (CING) Total Non-Current Liabilities (2021 - 2026)
Cingulate's (CING) quarterly Total Non-Current Liabilities came in at $2.3 million in Q4 2025, down 7.6% YoY from $2.4 million in Q4 2024, and up 93.63% on a QoQ basis from $1.2 million in Q3 2025.
Cingulate (CING) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Total Non-Current Liabilities data on file, last reported at $2.3 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 7.6% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (down 7.6% YoY) and the FY2025 annual result came in at $2.3 million, down 7.6% from the prior year.
- Total Non-Current Liabilities rose to $2.3 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.4 million in Q4 2024 to a low of $33145.0 in Q1 2024.
- A 5-year average of $825992.9 and a median of $557188.5 in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 92.16% — and 2025, when it surged 2686.84%.
- Tracing CING's Total Non-Current Liabilities over 5 years: stood at $866037.0 in 2021, then slumped by 41.08% to $510235.0 in 2022, then tumbled by 73.52% to $135099.0 in 2023, then jumped by 1703.77% to $2.4 million in 2024, then slipped by 7.6% to $2.3 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $2.3 million (Q4 2025), $1.2 million (Q3 2025), and $923698.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 968,455.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 968,455.00 |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 923,698.00 |
| Dec 31, 2024 | 2.44 Mn |
| Mar 31, 2024 | 33,145.00 |
| Dec 31, 2023 | 135,099.00 |
| Sep 30, 2023 | 234,160.00 |
| Jun 30, 2023 | 331,066.00 |
| Mar 31, 2023 | 422,802.00 |
| Dec 31, 2022 | 510,235.00 |
| Sep 30, 2022 | 604,142.00 |
| Dec 31, 2021 | 866,037.00 |